

Oesophago-gastric cancer committee meeting 9

Date: 23rd and 24th March 2017

Location: RCOG, London

Minutes: Final

Committee members present:		
Mr Cyrus Kerawala		(Present for notes 1 – 8)
Mark Harrison		(Present for notes 1 – 8)
David Brooks		(Present for notes 1 – 5)
Hugh Burnett		(Present for notes 1 – 8)
David Simpson		(Present for notes 1 – 8)
Mimi McCord		(Present for notes 1 – 8)
Venetia Wynter-Blyth		(Present for notes 1 – 8)
Orla Hynes		(Present for notes 1 – 8)
Robert Willert		(Present for notes 1 – 8)
Andrew Bateman		(Present for notes 1 – 8)
Naureen Starling		(Present for notes 1 – 8)
David Exon		(Present for notes 1 – 8)
Nick Maynard		(Present for notes 1 – 5)

In attendance:		
Katie Perryman-Ford	NICE Guideline Commissioning Manager	(Present for notes 1 – 5)
Matthew Prettyjohns	NGA Senior Health Economist	(Present for notes 1 – 8)
May Oo Khin	NGA Systematic Reviewer	(Present for notes 1 – 8)
Amy Burt	NGA Assistant Reviewer	(Present for notes 1 – 8)
Vicky Rowlands	NGA Project Manger	(Present for notes 1 – 8)
Hilary Eadon	NGA Guideline Lead	(Present for notes 1 – 8)
Nathan Broman	NGA Senior Systematic Reviewer	(Present for notes 1 – 8)

Observers:

None

Apologies:

David Brooks – Day 2; Nick Maynard – Day 2; Katie-Perryman-Ford – Day 2

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 9th meeting on Oesophago-gastric cancer.

No members of the public asked to observe the meeting.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Oesophago-gastric cancer.

Naureen Starling made a new declaration of interest:

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Naureen Starling	Consultant Medical Oncologist in GI Cancers & Associate Director of Clinical Research, The Royal Marsden	February 2017: Attended immuno-oncology summit in London arranged by BMS. Accommodation paid for by BMS. Chaired a session on vasculature/stroma for pancreatic cancer and the potential of immune-therapy drugs (e.g. nivolumab)	Financial personal, non-specific	Declare and participate. Nivolumab is not being discussed in this guideline.

3. Minutes of last meeting

The minutes of the last meeting were agreed as a true and accurate record of the meeting.

4. Presentations – Day 1

The Chair introduced Hilary Eadon who gave a presentation on the new NGA expenses policy and an overview of the overall guideline progress and outstanding work plan.

The Chair introduced Nathan Bromham who gave a presentation on diagnostic

reviews.

The Chair introduced Amy Burt, who gave presentations on the clinical evidence for topic 2.2 and 5.1

5. Questions and discussion – Day 1

The Committee discussed and agreed the draft recommendations for topics 2.2 and 5.1

The Committee reviewed the NICE editor's suggested amendments to the recommendations made at the previous meetings for topics 1.1, 1.2, 4.1, 4.5, 4.7, 4.8 and 4.11

6. Presentations – Day 2

The Chair introduced May Oo Khin, who gave a presentations on the clinical evidence for topics 3.1, 3.2 and 3.3

The Chair introduced Matthew Prettyjohns who gave a presentations on the health economic models for 3.1 and 4.5

The Chair introduced Amy Burt who gave a presentation on the protocol comparisons for 4.2

7. Questions and discussion – Day 2

The Committee discussed and agreed the draft recommendations for topics 3.1, 3.2 and 3.3

The Committee discussed the health economic results for topic 4.5 and agreed they did not change the recommendations

The Committee discussed and agreed the comparisons to be included in the evidence review for 4.2

8. Any other business

No service user or carer concerns were raised.

Date of next meeting: 10th April 2017

Location of next meeting: RCOG, London